Lilly to acquire Centessa for experimental sleep disorder drug

What happened: Eli Lilly and Company (NYSE:LLY) agreed to acquire Centessa Pharmaceuticals PLC (NASDAQ:CNTA) on March 31, 2023, in a deal valued at approximately $6.3 billion upfront and up to $7.8 billion including milestones. The acquisition price is $38 per share in cash, with a potential contingent value right worth up to $9 per share.

Market impact: This acquisition drives Eli Lilly's expansion into neuroscience, diversifying its portfolio beyond metabolic treatments. It signals a significant investment in sleep disorder treatments, with Centessa's pipeline seen as promising and potentially blockbuster. Centessa's stock surged 44.4% on the news, while Eli Lilly's stock experienced a slight uptick.

What to watch next: Investors should monitor the closing of the deal, expected in Q2 2023, subject to regulatory approvals and other customary closing conditions. Additionally, watch for updates on Centessa's clinical trials, particularly for its sleep medicine pipeline, which will validate the acquisition's potential. Lastly, track Eli Lilly's earnings in Q2 2023 to gauge the initial impact of this acquisition on its financials.